Hi pivalde. That was a great post. I believe those open label interim results were very positive. To see some efficacy at all in humans at this early stage is fantastic. They are the first human results after the animal models. As far as I know no other drug has demonstrated any efficacy against MSA. Most drugs fail during that step. PBT434 has crossed that step with strong evidence of efficacy in humans, with a double blind trial following close behind. The responders in the open label were all earlier stage, similar to the patients in the double blind. 201 is still a double blind, so by no means a slam dunk yet. but the risk of failure has been substantially reduced. I have no idea why the price would ease back on that news. Price manipulation maybe?
ATH Price at posting:
0.3¢ Sentiment: None Disclosure: Not Held
(20min delay)